ACA
Acorn Capital Advisors Portfolio holdings
AUM
$153M
This Quarter Return
-14.57%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$150M
AUM Growth
+$150M
(-19%)
Cap. Flow
+$5.7M
Cap. Flow
% of AUM
3.8%
Top 10 Holdings %
Top 10 Hldgs %
80.39%
Holding
22
New
1
Increased
7
Reduced
2
Closed
–
Top Buys
| 1 |
Y-mAbs Therapeutics
YMAB
|
$1.65M |
| 2 |
Aura Biosciences
AURA
|
$1.45M |
| 3 |
Candel Therapeutics
CADL
|
$1.2M |
| 4 |
Trevi Therapeutics
TRVI
|
$904K |
| 5 |
VYNE Therapeutics
VYNE
|
$520K |
Top Sells
| 1 |
Mural Oncology
MURA
|
$20.6K |
| 2 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$13.7K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $27.7M | 18.49% | 1,131,501 | – | – |
|
2
UroGen Pharma
URGN
$900M
| $16.8M | 11.18% | 1,516,303 | – | – |
|
|
3
Y-mAbs Therapeutics
YMAB
$388M
| $14.3M | 9.56% | 3,235,387 +373,562 | +13% | +$1.65M |
|
|
4
Trevi Therapeutics
TRVI
$883M
| $13.5M | 9% | 2,144,844 +143,796 | +7% | +$904K |
|
|
5
Candel Therapeutics
CADL
$318M
| $12.2M | 8.11% | 2,152,252 +212,608 | +11% | +$1.2M |
|
6
Puma Biotechnology
PBYI
$254M
| $11.7M | 7.78% | 3,940,052 | – | – |
|
|
BCAX
7
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $8.38M | 5.59% | 643,382 +1 | +0% | +$13 |
|
8
Protara Therapeutics
TARA
$120M
| $5.45M | 3.64% | 1,279,800 | – | – |
|
9
Terns Pharmaceuticals
TERN
$609M
| $5.44M | 3.63% | 1,971,264 | – | – |
|
|
OKUR
10
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $5.12M | 3.42% | 1,439,674 | – | – |
|
11
Verastem
VSTM
$569M
| $4.7M | 3.13% | 779,498 | – | – |
|
|
CYBN
12
Cybin
CYBN
$176M
| $4.66M | 3.11% | 734,394 +1 | +0% | +$6 |
|
13
Cardiff Oncology
CRDF
$140M
| $4.53M | 3.02% | 1,442,308 | – | – |
|
|
OPTN
14
DELISTED
OptiNose
OPTN
| $3.88M | 2.59% | 422,814 +1 | +0% | +$9 |
|
|
WHWK
15
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $2.03M | 1.35% | 1,139,363 -7,689 | -0.7% | -$13.7K |
|
16
X4 Pharmaceuticals
XFOR
$84.2M
| $1.75M | 1.17% | 7,310,650 | – | – |
|
|
17
Mural Oncology
MURA
$35.7M
| $1.6M | 1.07% | 1,269,715 -16,364 | -1% | -$20.6K |
|
|
18
Aura Biosciences
AURA
$389M
| $1.45M | 0.97% | +590,508 | New | +$1.45M |
|
19
BioAtla
BCAB
$26.7M
| $1.41M | 0.94% | 4,032,046 | – | – |
|
20
Q32 Bio
QTTB
$20.9M
| $1.33M | 0.88% | 803,425 | – | – |
|
|
21
VYNE Therapeutics
VYNE
$8.16M
| $1.24M | 0.83% | 785,938 +328,968 | +72% | +$520K |
|
22
Acrivon Therapeutics
ACRV
$42.2M
| $823K | 0.55% | 405,237 | – | – |
|